Skip to main content
LB

LEP Biomedical

This startup develops a biodegradable subconjunctival insert for post-operative inflammation in glaucoma drainage surgeries. The 3D-printed, drug-loaded mesh surrounded by a hydrogel provides controlled delivery of anti-inflammatory drugs, eliminating the need for post-surgical eye drops and improving surgical success rates.

Naas, IrelandFounded 20233300+ followers
Updated 3 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Product

Problem

Glaucoma drainage surgeries often face post-operative complications due to inflammation and scarring, leading to high failure and reoperation rates. Current treatments rely on patient-administered eye drops, which can be inconsistent and impact patient compliance, ultimately affecting surgical outcomes.

Solution

LEP Biomedical offers HyaGuard™, a biodegradable subconjunctival insert designed to provide controlled, localized delivery of anti-inflammatory drugs following glaucoma drainage surgery. The 3D-printed, drug-loaded mesh, surrounded by a hydrogel, is rapidly inserted in the subconjunctival space during the procedure. By eliminating the need for post-operative eye drops, HyaGuard™ ensures consistent drug delivery, reduces the risk of complications, and improves overall surgical success rates, potentially minimizing the need for follow-up procedures.

Target Audience

The primary target audience includes glaucoma surgeons seeking to improve surgical outcomes and reduce post-operative complications, as well as hospitals and insurers aiming to lower costs associated with follow-up care and reoperations.

Features

  • Biodegradable and biocompatible material for safe and complete absorption
  • Controlled drug release profile matched to the post-operative inflammatory response
  • Rapid insertion (<30 seconds) without specialized equipment or changes to surgical protocols
  • Lightweight (~8 mg dry) and small (1 mm high) design for patient comfort and minimal visibility
  • Tapered shape to fit securely under the conjunctiva without additional sutures or tissue glue
  • Validated platform technology with multiple drug payloads for various ophthalmic indications
This profile is AI-generated and may contain inaccuracies.